ZURA BIO LIMITED Net Income (Loss) Available to Common Stockholders, Basic
ZURA BIO LIMITED (ZURA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$99.35 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-19
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$45.88M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$20.04M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$15.99M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$17.44M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for fiscal 2025 was -$99.35M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for fiscal 2024 was -$45.39M.
- ZURA BIO LIMITED net income (loss) available to common stockholders, basic for fiscal 2023 was -$69.24M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 2 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 5 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 11 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$45.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$65.92M derived: sum of 2 quarters · filed 2026-03-19 | -$81.91M derived: sum of 3 quarters · filed 2026-03-19 | -$99.35M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$20.04M 10-Q · filed 2025-11-13 | -$36.03M derived: sum of 2 quarters · filed 2025-11-13 | -$53.47M 10-Q · filed 2025-11-13 | -$62.52M derived: sum of 4 quarters · filed 2026-03-19 | ||||
| 2025-06-30 | -$15.99M 10-Q · filed 2025-08-14 | -$33.44M 10-Q · filed 2025-08-14 | -$42.48M derived: sum of 3 quarters · filed 2026-03-19 | -$65.42M derived: sum of 4 quarters · filed 2026-03-19 | ||||
| 2025-03-31 | -$17.44M 10-Q · filed 2025-05-08 | -$26.49M derived: sum of 2 quarters · filed 2026-03-19 | -$49.43M derived: sum of 3 quarters · filed 2026-03-19 | -$62.10M derived: sum of 4 quarters · filed 2026-03-19 | ||||
| 2024-12-31 | -$9.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$31.99M derived: sum of 2 quarters · filed 2026-03-19 | -$44.66M derived: sum of 3 quarters · filed 2026-03-19 | -$45.39M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$22.94M 10-Q · filed 2025-11-13 | -$35.61M derived: sum of 2 quarters · filed 2025-11-13 | -$36.34M 10-Q · filed 2025-11-13 | -$42.62M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$12.67M 10-Q · filed 2025-08-14 | -$13.40M 10-Q · filed 2025-08-14 | -$19.67M derived: sum of 3 quarters · filed 2025-08-14 | -$27.94M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$730.00K 10-Q · filed 2025-05-08 | -$7.01M derived: sum of 2 quarters · filed 2025-05-08 | -$15.28M derived: sum of 3 quarters · filed 2025-05-08 | -$60.18M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$14.55M derived: sum of 2 quarters · filed 2025-03-25 | -$59.45M derived: sum of 3 quarters · filed 2025-03-25 | -$69.24M 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | -$8.27M 10-Q · filed 2024-11-07 | -$53.17M derived: sum of 2 quarters · filed 2024-11-07 | -$62.97M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$44.90M 10-Q · filed 2024-08-13 | -$54.70M 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$9.79M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$32.39M 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | -$1.10M 10-Q · filed 2023-11-13 | -$2.03M derived: sum of 2 quarters · filed 2023-11-13 | -$9.85M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$925.00K 10-Q · filed 2023-08-14 | -$8.74M 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$7.82M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |